Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Comutational profiles and survival benefits from enasidenib appear to differ based on presence of the IDH2 R140 or IDH2 R172 mutation, warranting additional research to clarify the influence of the various mutations on treatment outcomes.
Format: Microsoft PowerPoint (.ppt)
File Size: 136 KB
Released: June 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings